World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
86
Citations
36526
World Ranking
13915
National Ranking
7062

Overview

Christine Chevreau is affiliated with DuPont in the United States. Their research primarily focuses on medicine, with significant contributions across several subfields including pulmonary and respiratory medicine, oncology, surgery, rheumatology, and pathology and forensic medicine.

The scientist has published an extensive number of papers, with the main fields of study encompassing:

  • Medicine

They have worked extensively on topics related to cancer and related treatments. The main areas of research interest include:

  • Sarcoma Diagnosis and Treatment
  • Renal cell carcinoma treatment
  • Cancer Immunotherapy and Biomarkers
  • Vascular Tumors and Angiosarcomas
  • Cancer Genomics and Diagnostics
  • Bladder and Urothelial Cancer Treatments
  • Cardiac tumors and thrombi

Christine Chevreau's work has appeared in a number of frequently featured publication venues such as:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • European Journal of Cancer
  • The Lancet Oncology
  • Cancers

They have collaborated regularly with other researchers, including:

  • Jean-Yves Blay
  • Emmanuelle Bompas
  • Nicolas Penel
  • Sophie Piperno-Neumann
  • Florence Duffaud

Among the recent papers associated with the broader research themes of this scientist are:

  • Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma, 2021, New England Journal of Medicine
  • Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial, 2020, The Lancet Oncology
  • Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial, 2020, Cancer
  • Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial, 2020, The Lancet Oncology
  • Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial, 2022, The Lancet Oncology

Best Publications

  • Sorafenib in advanced clear-cell renal-cell carcinoma.

    Bernard Escudier;Tim Eisen;Walter M. Stadler;Cezary Szczylik

  • Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

    Bernard Escudier;Anna Pluzanska;Piotr Koralewski;Alain Ravaud

  • Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

    Bernard Escudier;Tim Eisen;Walter M. Stadler;Cezary Szczylik

  • Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma

    Sylvie Negrier;Bernard Escudier;Christine Lasset;Jean-Yves Douillard

  • Prognostic Scoring System for Primary CNS Lymphomas: The International Extranodal Lymphoma Study Group Experience

    Andrés J M Ferreri;Jean Yves Blay;Michele Reni;Felice Pasini

  • Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.

    Arnaud Méjean;Alain Ravaud;Simon Thezenas;Sandra Colas

  • Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study

    Nicolas Penel;Binh Nguyen Bui;Jacques-Olivier Bay;Didier Cupissol

  • Randomized Phase III Study Comparing Paclitaxel/Cisplatin/ Gemcitabine and Gemcitabine/Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Cancer Without Prior Systemic Therapy: EORTC Intergroup Study 30987

    Joaquim Bellmunt;Hans von der Maase;Graham M. Mead;Iwona Skoneczna

  • Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.

    Toni K. Choueiri;Piotr Tomczak;Se Hoon Park;Balaji Venugopal

  • High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series.

    J Y Blay;T Conroy;C Chevreau;A Thyss

  • Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

    Thomas Powles;Michiel S van der Heijden;Daniel Castellano;Matthew D Galsky

  • Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d’Immunothérapie

    S. Négrier;B. Escudier;F. Gomez;J.-Y. Douillard

  • Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial.

    Maud Toulmonde;Nicolas Penel;Julien Adam;Julien Adam;Christine Chevreau

  • Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study.

    M de Forni;Myriam Malet-Martino;P Jaillais;R Shubinski

  • Prediction of Carboplatin Clearance From Standard Morphological and Biological Patient Characteristics

    Etienne Chatelut;Pierre Canal;Valérie Brunner;Christine Chevreau

  • Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial

    Axel Le Cesne;Isabelle Ray-Coquard;Binh Nguyen Bui;Antoine Adenis

  • Improved survival using specialized multidisciplinary board in sarcoma patients.

    J.-Y. Blay;P. Soibinet;N. Penel;E. Bompas

  • Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial

    Sylvie Négrier;Gwenaëlle Gravis;David Pérol;Christine Chevreau

  • Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.

    Florence Duffaud;Olivier Mir;Pascaline Boudou-Rouquette;Sophie Piperno-Neumann

  • Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up.

    N. Penel;A. Le Cesne;B.N. Bui;D. Perol

Frequent Co-Authors

Jean-Yves Blay
Jean-Yves Blay Claude Bernard University Lyon 1
François Bertucci
François Bertucci Aix-Marseille University
Axel Le Cesne
Axel Le Cesne Institut Gustave Roussy
Bernard Escudier
Bernard Escudier Institut Gustave Roussy
Antoine Italiano
Antoine Italiano University of Bordeaux
Isabelle Ray-Coquard
Isabelle Ray-Coquard Claude Bernard University Lyon 1
Alain Ravaud
Alain Ravaud University of Bordeaux
Stéphane Oudard
Stéphane Oudard Hôpital Européen Georges-Pompidou
Laurence Albiges
Laurence Albiges Institut Gustave Roussy
Karim Fizazi
Karim Fizazi University of Paris-Saclay

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

As you consider studying Medicine in the USA, it’s valuable to explore related online degrees and alternative career pathways that support the healthcare ecosystem. These flexible academic options can help you start or advance your medical career based on your interests and goals.

For those looking to become nurses quickly and without the stress of strict admission exams, you can find an lpn program no entrance exam. This can be a practical entry point into nursing, offering a more streamlined admission process.

If you’re interested in the administrative side of healthcare, accredited online health administration programs allow you to develop leadership skills and pursue roles in management, policy, and organization within medical settings.

Already an RN? Accelerate your career with rn to fnp bridge programs, which enable registered nurses to earn their advanced practice credentials and become Family Nurse Practitioners in less time.

Those passionate about wellness and preventive care can earn a bachelor's in nutrition online, opening doors to careers in dietetics, research, and health education.

These related online degrees offer flexible, accessible ways to enter or grow within the healthcare field, catering to a wide range of interests and career ambitions.

Best Scientists Citing Christine Chevreau

Trending Scientists